$2.90
3.57% yesterday
Nasdaq, May 20, 10:16 pm CET
ISIN
US45256X1037
Symbol
IBRX
Sector
Industry

ImmunityBio Inc Stock price

$2.90
+0.39 15.54% 1M
-1.98 40.51% 6M
+0.34 13.28% YTD
-4.14 58.81% 1Y
-1.01 25.83% 3Y
-2.15 42.57% 5Y
-31.74 91.63% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.10 3.57%
ISIN
US45256X1037
Symbol
IBRX
Sector
Industry

Key metrics

Market capitalization $2.56b
Enterprise Value $3.32b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 106.39
P/S ratio (TTM) P/S ratio 81.99
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 10,238.41%
Revenue (TTM) Revenue $31.22m
EBIT (operating result TTM) EBIT $-313.42m
Free Cash Flow (TTM) Free Cash Flow $-376.90m
Cash position $61.59m
EPS (TTM) EPS $-0.58
P/E forward negative
P/S forward 26.51
EV/Sales forward 34.40
Short interest 30.11%
Show more

Is ImmunityBio Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

ImmunityBio Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a ImmunityBio Inc forecast:

5x Buy
100%

Analyst Opinions

5 Analysts have issued a ImmunityBio Inc forecast:

Buy
100%

Financial data from ImmunityBio Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
31 31
10,307% 10,307%
100%
- Direct Costs 17 17
16% 16%
54%
14 14
173% 173%
46%
- Selling and Administrative Expenses 128 128
27% 27%
410%
- Research and Development Expense 183 183
10% 10%
586%
-297 -297
9% 9%
-950%
- Depreciation and Amortization 17 17
16% 16%
54%
EBIT (Operating Income) EBIT -313 -313
9% 9%
-1,004%
Net Profit -409 -409
32% 32%
-1,310%

In millions USD.

Don't miss a Thing! We will send you all news about ImmunityBio Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ImmunityBio Inc Stock News

Neutral
Business Wire
9 days ago
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced certain operational results following approval of the permanent J-code (J9028) in January 2025, as well as its financial results for the first-quarter ended March 31, 2025. With the issuance of the permanent J-code (J9028) in January 2025, ImmunityBio has seen increased sales...
Positive
Seeking Alpha
15 days ago
ImmunityBio, Inc.'s sBLA for Anktiva was unexpectedly rejected by the FDA, contradicting prior positive feedback and approval for a similar indication. The market reacted negatively, dropping IBRX shares to around $2.00, but the trading volume was not extremely high. Despite the setback, I maintain a conviction level of 3 out of 5 for IBRX, focusing on potential long-term gains and upcoming cat...
Neutral
Business Wire
16 days ago
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that the Company received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) for the supplemental biologics license application (sBLA) for use of ANKTIVA plus Bacillus Calmette-Guerin (BCG) in BCG-unresponsive non-muscle invasive bladder cancer (N...
More ImmunityBio Inc News

Company Profile

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in Culver City, CA.

Head office United States
CEO Richard Adcock
Employees 680
Founded 2014
Website www.immunitybio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today